Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
News Nov 14, 2008
DNA2.0 has announced that the company’s RNAissance genes had been used to shed new light on the mechanisms that ensure that each daughter cell receives a full complement of genetic material when cells divide.
The study, published this week in Nature Cell Biology, was a collaboration between DNA2.0 and researchers in Dr. Jonathon Pines’ group at the Wellcome/CR UK Gurdon Institute and Department of Zoology at Cambridge.
DNA2.0’s RNAissance genes are widely used to ensure that phenotypes obtained when cells are treated with RNAi are not the unintended result of off-target effects, the company says. For the work reported in Nature Cell Biology, Dr. Pines went a step further. He made RNAi-resistant versions of both a wildtype and a mutated protein (Cdc20).
In the mutated version, all 23 lysines found in the wildtype protein were changed to arginine, a change that prevented the mutant Cdc20 from becoming ubiquitinated. By eliminating the natural Cdc20 from cells using RNAi, the Cambridge group was able to show that ubiquitination of Cdc20 is required to prevent a cell from dividing before all of its chromosomes are lined up on the mitotic spindle. This cell cycle checkpoint is essential to prevent serious genetic damage in animals from yeast to humans.
“We were delighted to help Dr. Pines by designing and making our RNAissance genes,” said Dr. Jeremy Minshull, the DNA2.0 coauthor of the study. “Making RNAi-resistant genes that encode mutant versions of cellular proteins has the potential to help us understand the molecular details of many biological processes, as Dr Pines’ group has so elegantly shown.”
Eliminating the natural copy of a protein and replacing it with a mutated version has previously been possible only through genetic manipulations that are largely restricted to microbial systems. Researchers now have a tool to aid them in studying the molecular basis of cellular phenotypes that even allows the modification of genes and proteins that are essential for a cell’s survival.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE